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Abstract  35 
Clinical studies have linked the increased consumption of fructose to the development of obesity, 36 
dyslipidemia and impaired glucose tolerance, and a role in hepatosteatosis development is 37 
presumed. Fructose can undergo a non-enzymatic reaction from which advanced glycation 38 
endproducts (AGEs) are derived, leading to the formation of dysfunctional, fructosylated proteins, 39 
however the in vivo formation of AGEs from fructose is still less known than that from glucose.  40 
In the present study C57Bl/6J mice received 15% (w/v) fructose (FRT) or 15% (w/v) glucose 41 
(GLC) in water to drink for 30 weeks, resembling human habit to consume sugary drinks. At the 42 
end of protocol both FRT and GLC drinking mice had increased fasting glycaemia, glucose 43 
intolerance, altered plasma lipid profile, and marked hepatosteatosis. FRT mice had higher hepatic 44 
triglycerides deposition than GLC, paralleled by a greater increased expression and activity of the 45 
sterol regulatory element-binding protein 1 (SREBP1), the transcription factor responsible for the 46 
de novo lipogenesis, and of its activating protein SCAP. LC-MS analysis showed a different pattern 47 
of AGEs production in liver tissue between FRT and GLC mice, with larger amount of 48 
carboxymethyl lysine (CML) generated by FRT. Double immunofluorescence and 49 
coimmunoprecipitation analysis revealed an interaction between CML and SCAP that could lead to 50 
prolonged activation of SREBP1.  51 
Overall, the high levels of CML and activation of SCAP/SREBP pathway associated to high 52 
fructose exposure here reported may suggest a key role of this signaling pathway in mediating 53 
fructose-induced lipogenesis.  54 
 55 
 56 
 57 
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Introduction 61 
Many clinical studies have linked the rising consumption of soft drinks added with fructose to the 62 
development of obesity, dyslipidemia, insulin resistance, impaired glucose tolerance, and 63 
hypertension in adults (6,9,19, 26). Interestingly, clinical data show that inclusion of fructose in the 64 
diet for 10 weeks leads to a greater increase in hepatic lipid synthesis than that occurring with an 65 
equal amount of glucose (42).  66 
Lipid metabolism is regulated by the sterol regulatory element binding proteins (SREBP) family,  67 
comprising three subtypes: SREBP-1a and SREBP-1c, which are generated by alternative splicing, 68 
and SREBP-2. SREBP-1c, expressed in most tissues with a greater prevalence than SREBP1a in 69 
liver and adrenal glands, is in charge of governing fatty acid and triacylglyceride metabolism, while 70 
SREBP-2, ubiquitously expressed,  is involved in the regulation of cholesterol metabolism. Both 71 
SREBP-1 and SREBP-2 are synthesized as membrane proteins in the endoplasmic reticulum (ER) 72 
forming a complex with the SREBP-cleavage activating protein (SCAP). In spite of the distinct 73 
roles of the SREBPs in lipid metabolism, they are both subjected to the identical processing 74 
pathway (37): when TG or cholesterol synthesis are required, SCAP shuttles SREBPs from the 75 
endoplasmic reticulum (ER) to the Golgi, where they are cleaved by two proteases and enter the 76 
nucleus, bind to the sterol-regulatory elements in the promoters of target genes and increase 77 
transcription of lipogenic or cholesterologenic enzymes (17). Interestingly, SREBP-1 and SREBP-2 78 
processing is triggered by different types of stimuli: while SREBP-1 activation depends primarily 79 
on insulin signaling and nutritional status, SREBP-2 is sensitive to membrane sterols level (37). 80 
The liver is the main organ in which fructose metabolism takes place rapidly leading to increased 81 
hepatic synthesis of glycogen, fatty acids and triglycerides (TG) (45). Nonalcoholic fatty liver 82 
disease (NAFLD) is the most common disorder in industrialized countries, affecting 15-20% of the 83 
general population (49) and epidemiological studies have indicated that the development of NAFLD 84 
may be associated with excessive fructose consumption (35,50). 85 
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Among the chemical properties of fructose, a non-enzymatic pathway known as the Maillard 86 
reaction is reported, in which fructose reacts with the aminic groups of proteins. After this reaction, 87 
the anomerisation equilibrium of fructose is displaced toward the open form of the sugar, which is 88 
highly reactive, especially compared to the forms derived from glucose (43). The Maillard reaction 89 
is also one of the “classic” pathways from which the advanced glycation endproducts (AGEs) are 90 
derived. It is known that a mixed class of toxic AGEs can be produced from the reduction of 91 
glucose (49): CML (carboxymethyl lysine) and pentosidine are obtained through an oxidative 92 
process, while MGO (methylglyoxal) and GLAP (glyceraldehyde-derived pyridinium compound) 93 
through a non-oxidative process. Additionally, glucose is known to form AGE alpha-oxoaldehydes, 94 
including GOLD (glyoxal-lysine dimer) and MOLD (methylglyoxal-lysine dimer), through the 95 
polyol pathway (41). AGEs can exert a direct interference with cellular proteins function or a 96 
receptor-mediated action, the latter being chiefly attributed to bonding with RAGE (Receptor for 97 
AGE) (4). The interaction between AGEs and RAGE leads to intracellular signals responsible for 98 
activation of pro-inflammatory transcription factors, such as NFkB (nuclear factor-kB) (3). 99 
The Maillard reaction undertaken by fructose leads to the formation of altered, fructosylated 100 
proteins, which are potentially toxic, indicating that fructose, together with glucose, plays an 101 
important role in the formation of AGEs. So far, the in vivo formation of fructose-derived AGEs has 102 
only been demonstrated in one study, and only through immunochemical analysis, without 103 
reporting a description of their chemical structure (44). Thus, the chemical structure and toxicity of 104 
AGEs molecules specifically derived from fructose are less well known than those derived from 105 
glucose.  106 
It might be hypothesized that the entrance of fructose in hepatocytes, where fructose is metabolized, 107 
leads to the fructosylation of cytoplasmic proteins, causing a loss of their functionality and 108 
regulation, thus contributing to liver  alterations.  109 
This study is aimed to characterized fructose-derived AGEs and to investigate  their target proteins 110 
in liver by a comparative analysis between fructose and glucose-drinking mice. 111 
5 
 
Materials and Methods 112 
All compounds were purchased from Sigma Chemical Co. (St. Louis, MO, USA) and all primary 113 
antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), unless otherwise stated. 114 
Animals and treatments 115 
Male C57Bl6/N mice (Charles River Laboratories, Calco, LC, Italy) aged 5 weeks were cared for in 116 
compliance with the European Council directives (No. 86/609/EEC) and with the Principles of 117 
Laboratory Animal Care (NIH No. 85–23, revised 1985). The scientific project was approved by the 118 
local ethical committee. The animals were divided into three groups of 8-10 mice: CTRL-group, 119 
drinking tap water; FRT-group, drinking a 15% fructose solution; GLC-group, drinking a 15% 120 
glucose solution. All groups were fed with a standard lab chow and received drink and food ad 121 
libitum.  122 
Body weight, drink and food intake were recorded weekly. Fasting glycemia was measured at the 123 
start of the protocol and every 8 weeks by saphenous vein puncture using a glucometer 124 
(GlucoGmeter, Menarini Diagnostics, Firenze, Italy). After 30 weeks mice were anesthetized and 125 
killed by cardiac exsanguination. Blood was collected and plasma isolated. The liver was rapidly 126 
removed. A portion was cryoprotected in OCT (Optimal Cutting Temperature) compound (VWR, 127 
Milano, Italy) and frozen  in N2 for cryostatic preparations. Other portions were frozen in N2 and 128 
stored at −80°C for protein analysis.  129 
Oral glucose tolerance test 130 
Before killing, a glucose solution was administered orally at 2 g/kg b.w after a fasting period of 6 h. 131 
Plasma glucose levels were measured every 30 minutes for 2 hrs after glucose loading. 132 
Biochemical parameters 133 
Plasma lipid profile was determined by standard enzymatic procedures using reagent kits 134 
(triglycerides (TG), cholesterol, high-density lipoproteins (HDL), low-density lipoproteins (LDL): 135 
Hospitex Diagnostics, Florence, Italy; non-esterified fatty acid (NEFA): Wako Chemicals,Neuss, 136 
Germany).  137 
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Plasma insulin level was measured using an enzyme-linked immunosorbent assay (ELISA) kit 138 
(Mercodia AB, Uppsala, Sweden). 139 
For tissue TG and cholesterol content determination, colorimetric assay kits were used after lipid 140 
extraction (TG: Triglyceride Quantification Kit, Abnova Corporation, Aachen, Germany; 141 
cholesterol: Hospitex Diagnostics). 142 
Oil red staining 143 
Liver lipid accumulation was evaluated by oil red staining on 4 m cryostatic sections. Stained 144 
tissues were viewed under an Olympus Bx4I microscope (10x magnification) with an 145 
AxioCamMR5 photographic attachment (Zeiss, Gottingen, Germany). The sections were analyzed 146 
on six fileds/slide and scored by a blinded pathologist using the NAFLD activity score (NAS) 147 
system (21). 148 
Preparation of tissue extracts 149 
Liver cytosolic, nuclear, and total proteins were extracted as previously described (28). Protein 150 
content was determined using the Bradford assay and samples were stored at -80°C until use.  151 
AGEs analysis with LC-MS 152 
Pentosidine, GOLD, MOLD, CML, and GLAP, were evaluated on total liver extracts after 153 
hydrolisis with 0.6 M trichloroacetic acid and 50 µL of hydrochloric acid 6 M  for 12 hours at 60°C. 154 
The chromatographic separations were run on an Ultimate 3000 HPLC (Dionex, Milan, Italy) 155 
coupled to a high resolving power mass spectrometer (HRMS) LTQ Orbitrap (Thermo Scientific, 156 
Rodano, Italy), equipped with an atmospheric pressure interface and an ESI ion source. The 157 
samples were analyzed using an Reverse Phase C18 column (Phenomenex Synergi 150 × 2.1 mm, 3 158 
μm particle size) at a flow rate of 200 μL/min. A gradient mobile phase composition was adopted: 159 
95/5 to 40/60 in 25 min, 5 mM heptafluorobutanoic acid/acetonitrile. The monitored protonated 160 
molecular ions were 205.1188 m/z for CML, 255.1344 m/z for GLAP, 341.2189 m/z for MOLD, 161 
327.2032 m/z for GOLD and 379.2094 m/z for pentosidine. Quantitative determination of all the 162 
analytes were done by using pentosidine calibration data. 163 
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Western blotting.  164 
Equal amounts of total, cytosolic or nuclear proteins were separated by SDS-PAGE and 165 
electrotransferred to nitrocellulose membrane (GE-Healthcare Europe, Milano, Italy). Mouse anti-166 
NFkBp65, rabbit anti-SREBP1 and mouse anti-SREBP2 antibodies were probed on both cytosolic 167 
and nuclear extracts. Goat anti-ICAM-1 (intercellular adhesion molecule-1) and anti-CTGF 168 
(connective tissue growth factor), rabbit anti-SCAP, anti-ACC (Cell Signaling Technology, Danver, 169 
MA,USA), anti-HMGR (Millipore, Temecula, CA, USA), anti-apoB, anti-CPT1-L, and anti-RAGE 170 
were probed on total extracts. Rabbit anti-apoB was also probed on 10 ul of plasma samples. 171 
Proteins were detected with ECL chemiluminescence substrate (GE-Healthcare) and quantified by 172 
densitometry using analytic software (Quantity-One, Bio-Rad). β-actin served as loading control for 173 
total and cytosolic protein extracts, and lamin-B1 for nuclear extracts. 174 
Immunofluorescence 175 
Localization of SCAP, SREBP1, CML and MGO was assessed on 4 m liver cryostatic sections by 176 
indirect immunofluorescence. Sections were blocked for 1 h with 3% BSA in PBS added with 177 
unconjugated goat anti-mouse IgG to prevent mouse-on-mouse interferences. Thus, sections were 178 
incubated overnight with rabbit anti-SCAP, rabbit anti-SREBP1, mouse anti-CML (Trans-Genic, 179 
Kobe, Japan) or mouse anti-MGO (Trans-Genic) primary antibodies and for 1 h with fluorescent 180 
secondary antibodies (Dako, Glostrup, Denmark): TRITC-conjugated anti-rabbit IgG or biotin-181 
conjugated anti-mouse IgG followed by FITC-conjugated streptavidin. Negative controls were 182 
prepared incubating sections with secondary antibodies. Sections were examined using a Leica 183 
Olympus epifluorescence microscope (Olympus Bx4I) and digitised with a high resolution camera 184 
(Zeiss).  185 
Double immunofluorescence. 186 
Double immunofluorescence was performed for SCAP and CML on liver cryostatic sections. After 187 
blocking, sections were incubated with a mix of primary antibodies  for 1 hour. After washing, 188 
sections were incubated with a mix of labelled secondary antibodies. The images were colour-189 
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combined and assembled into photomontages by using Adobe Photoshop (Universal Imaging, West 190 
Chester, PA). 191 
Co-immunoprecipitation. 192 
Equal amounts of total proteins (500 g) were incubated overnight with SCAP rabbit-polyclonal 193 
antibody (2 g). The antibody-antigen complexes were then incubated with fresh Protein A 194 
Sepharose beads for 3 h. SDS Laemmli buffer was added to the beads and eluted proteins were 195 
subjected to SDS–PAGE and immunoblotted with mouse anti-CML monoclonal antibody and, after 196 
stripping, with rabbit anti-SCAP antibody. 197 
Statistical analysis 198 
All values are expressed as means ± SD and were analyzed by Anova test followed by Bonferroni's 199 
post-test. A P value <0.05 was considered statistically significant.  200 
Results 201 
Fructose and glucose drinking in mice induces alterations in body weight, glucose tolerance 202 
and plasma lipid profile. 203 
The daily drink intake in the FRT and GLC drinking groups was markedly higher than in the CTRL 204 
group, drinking tap water. Moreover, GLC intake was also significantly higher than FRT, but 205 
despite that, the total daily caloric intake was similar among the groups, being proportionally 206 
reduced the food intake (Table 1).  207 
As shown in Table 1, mice drinking FRT or GLC for 30 weeks showed a significant increase in 208 
body weight compared to CTRL mice (+31%).  209 
Fasting glycemia was significantly higher both in FRT and in GLC groups compared to CTRL 210 
group (Table 1). During OGTT (Fig. 1A), the glycemic curves of FRT and GLC mice were 211 
markedly moved away from CTRL curve at every time-point after glucose charge. Plasma insulin 212 
level was slightly increased in GLC group and in a greater extent in FRT group, with respect to 213 
CTRL, without reaching any statistical significance (Table 1).  214 
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In comparison with CTRL animals, FRT mice showed alterations in plasma lipid profile (Table 2) 215 
featured by increased levels of TG (+43%), cholesterol  (+37%), and LDL (+80%), paralleled by a 216 
decrease in NEFA (-24%). GLC mice only showed a trend to dyslipidemia that didn’t reach the 217 
statistical significance, excepting for HDL level (-16%), and for NEFA level that, conversely to 218 
FRT group, was increased (+20%) compared to CTRL. 219 
Fructose and glucose drinking increases liver TG and cholesterol content and induces 220 
hepatosteatosis. 221 
Hepatic homogenates of FRT mice showed a marked increase in TG and cholesterol content 222 
compared to CTRL (+100% and +50%, respectively). In liver homogenates from GLC mice an 223 
increase in cholesterol content similar to FRT was found (+42% of the CTRL value), while the TG 224 
level tend to increase compared  to CTRL, but remained significantly lower than in FRT group (-225 
60%) (Fig. 1B). 226 
Oil red staining of liver sections (Fig. 1C-E) highlighted a marked lipid deposition both in FRT (D) 227 
and in GLC mice (E) compared to CTRL (C), resembling a condition of non-alcoholic fatty liver 228 
disease, with different histopathological features. FRT mice liver showed enlarged hepatocytes with 229 
periportal macrovacuolar steatosis. In contrast, liver of GLC mice showed a microvesicular steatosis 230 
with a panlobular dissemination. A significantly higher steatosis grade was detected in FRT 231 
compared to GLC mice, conferring an overall NAS score of 5.2±1.3 to FRT vs. 3.8±0.9 to GLC 232 
mice liver (P<0.05) (Fig. 1F). 233 
Fructose and glucose drinking enhances TG and cholesterol synthesis through activation of 234 
SCAP-SREBP signalling. 235 
To further investigate the greater lipogenic effect of FRT with respect to GLC, we assessed the 236 
expression and activation of SREBP1c, SREBP2 and their activating protein SCAP by western 237 
blotting analysis (Fig. 2).  238 
SCAP was markedly up-regulated in FRT and GLC mice compared to CTRL (Fig. 2A,B), in a 239 
significantly greater extent in FRT than in GLC. Both SREBP1c and SREBP2 were up-regulated in 240 
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FRT and GLC groups compared to CTRL (Fig. 2C-H). Specifically, the 68 kDa active form (Fig. 241 
2C,E) and the 125 kDa inactive form (Fig. 2F,H) of SREBP1c were significantly more expressed in 242 
liver of FRT mice than in GLC. In contrast, SREBP2 was equally activated in FRT and GLC liver 243 
(Fig. 2D,E), while inactive form of SREBP2 was more expressed in GLC liver than in FRT, 244 
without reaching significant difference (Fig. 2G,H).  The activation of the SCAP/SREBP pathway 245 
is confirmed by the increased expression in FRT and GLC mice liver of both the SREBP1c target 246 
gene encoding acetyl coenzyme A carboxylase (ACC), one of the enzymes that promote triglyceride 247 
synthesis, (Fig. 3A,B), and the SREBP2 target gene encoding hydroxymethyl coenzyme A 248 
reductase (HMGR), the rate limiting enzyme of the cholesterol synthesis (Fig. 3C,D). Notably, the 249 
expression of ACC is about 35% greater in FRT than in GLC mice liver (Fig. 3B) according to the 250 
higher activation of SREBP1c. 251 
ApoB100 protein level was measured in plasma and liver as marker of VLDL secretion (Fig. 3E), 252 
while the expression of carnitine palmitoyl transferase 1 (CPT1-L) (Fig. 3G) indicates the 253 
efficiency of -oxidation. Any significant differences were seen in ApoB100 plasma-to-liver 254 
protein level (Fig. 3F) and in liver expression of CPT1-L (Fig. 3H), among the three groups, 255 
although a trend to a reduction of CPT1-L level was seen in GLC mice.  256 
Fructose and glucose drinking enhances AGEs generation and activates RAGE signalling. 257 
As shown in Table 3, all AGEs here measured were markedly increased in liver homogenates of 258 
FRT and GLC mice compared to CTRL. Most notably, GLAP and MOLD highest levels were 259 
detected in the liver of GLC-drinking group, while GOLD and CML were produced in the greatest 260 
amount in the liver from FRT group (Table 3). The receptor for AGEs, RAGE, was up-regulated 261 
both in FRT and GLC mice compared to CTRL (+100%) (Fig. 4A,B) and the downstream 262 
signalling was activated as demonstrated by the nuclear translocation of NFkB-p65 (Fig. 4C,D). As 263 
consequence, we found increased levels of the NF-kB-dependent protein ICAM-1 in both sugar-264 
drinking groups (Fig. 4E,F), and a slight, but not significant, increase of an early marker of fibrosis, 265 
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CTGF (Fig. 4E,F), even if morphological signs, as collagen I and IV deposition, were still not 266 
detectables (data not shown). 267 
CML colocalizes with SCAP in liver of fructose drinking mice. 268 
Immunofluorescence analysis on liver sections from FRT mice showed a prevalent nuclear 269 
localization for SREBP1c (Fig. 5A,B), consistent with its activation, and a cytosolic perinuclear 270 
localization for SCAP (Fig. 5D,E). CML localized mainly in cytosol of hepatocytes (Fig. 5G,H), 271 
with a perinuclear distribution similar to SCAP. Interestingly, MGO was detected mainly in the 272 
endothelium and at the plasmamembrane of hepatocytes (Fig. 5J,K).  273 
Double immunofluorescence studies in liver of FRT group confirmed that CML colocalizes with 274 
SCAP in the perinuclear zone of the hepatocytes (Fig. 6A-F).  275 
CML modifies SCAP in liver of fructose drinking mice. 276 
Finally, co-immunoprecipitation assay has been performed to evaluate SCAP glycosylation by 277 
CML (Fig. 6G,H). SCAP was immunoprecipitated with Protein A Sepharose, electrophoresed and 278 
blotted on nitrocellulose membrane. Membrane was then exposed to CML antibody, revealing a 279 
complex between SCAP and CML in liver of FRT mice. 280 
Discussion 281 
This study clearly demonstrates a significant activation of SCAP/SREBP pathway and the 282 
following increase in de novo lipogenesis, which were associated to high levels of fructose-derived 283 
AGEs in the liver of mice chronically exposed to high fructose intake. 284 
Reducing sugars, as fructose and glucose, react spontaneously with amino groups of proteins to 285 
advanced glycation end products (AGEs) (27). Although glucose plays a primary role in the 286 
formation of AGEs, it is now known that fructose undergoes the same non-enzymatic glycation 287 
reaction at a much faster rate. When fructose assumption with foods or beverages is remarkable, its 288 
high reactivity may substantially contribute to the tissue formation of AGEs and lead to cellular 289 
alterations and dysfunction (38).  290 
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Our study shows for the first time a different pattern of hepatic AGEs between FRT and GLC 291 
detected by LC-MS. In detail, FRT generates higher levels of AGEs derived from glyoxal, such as 292 
GOLD and CML, while we found more AGEs derived from methylglyoxal, MOLD and GLAP, in 293 
GLC mice. These differences may just reflect the dissimilar pathways and rates of FRT and GLC 294 
metabolism. Moreover, methylglyoxal is less toxic toward hepatocytes than glyoxal being a better 295 
substrate for the carbonyl detoxifying enzymes, while the rate of metabolism of glyoxal by 296 
hepatocyte metabolizing enzymes is much faster than for methylglyoxal (39). This could account 297 
for the greater accumulation of GOLD and CML in FRT mice. 298 
So far there are limited data directly comparing the effects of fructose and glucose in vivo on lipid 299 
metabolism, the few existing using very high concentration of sugars for a short time (22,40,42,48), 300 
and even less on AGEs generation (1,27).  301 
For this reason, the peculiarities of the present study are the characterization of in vivo AGEs 302 
generation from fructose and the suggestion of their involvement in the increased hepatic lipid 303 
synthesis, in comparison with glucose, through an experimental protocol based on low sugar 304 
concentrations given for a long time, mimicking the diffused human habit to daily drink sweetened 305 
beverages.  306 
In physiological conditions, the potential sources of TG that contribute to fatty liver development 307 
are NEFA coming from the hydrolysis of fatty acids stored in adipose tissue, dietary fatty acids and 308 
newly synthesized fatty acids through de novo lipogenesis (11). Moreover, an impairment of the 309 
lipid -oxidation rate or of the hepatic triglycerides clearance by VLDL may also lead to hepatic 310 
lipid accumulation (46). In the present study FRT drinking mice had lower plasma NEFA than GLC 311 
mice, while both the liver expression of CPT-1, the rate limiting enzyme of mitochondrial -312 
oxidation, and the ratio between plasma and liver levels of ApoB100, the structural component of 313 
VLDL, did not differ in FRT and GLC mice. These data indicate for the first time that the de novo 314 
synthesis is the main pathway responsible for the higher lipid accumulation in liver of FRT mice 315 
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with respect to GLC, in which other mechanisms, such as reduction of -oxidation and higher 316 
hydrolysis of adipose fat, may contribute to hepatic steatosis, as previously suggested by other 317 
authors (30).  318 
Liver is the main tissue involved in fructose handling and de novo lipogenesis (18), and many 319 
studies have shown that fructose plays a specific role in the pathogenesis of hepatosteatosis and 320 
metabolic syndrome due to differential hepatic fructose metabolism (25,32,33). However, the 321 
molecular mechanisms by which high fructose diets induce abnormalities in liver TG metabolism 322 
are not fully understood. 323 
It has been observed that a simultaneous induction of glycolitic and lipogenic genes is a salient 324 
feature when dietary glucose is replaced with fructose. Indeed, fructose ingestion at high doses 325 
increases expression of the genes encoding for lipogenic enzymes via the activation of SREBP1 in 326 
the liver (29). Thus, we have analyzed the expression of SREBP1c, SREBP2 and of their chaperone 327 
protein SCAP in the liver of FRT and GLC drinking mice.  328 
In our work, chronic exposure to low levels of both FRT and GLC induced the activation of the 329 
SCAP/SREBP system. Notably, there was a marked difference in SCAP expression between FRT 330 
and GLC mice, being higher in FRT, and this could be crucial for the greater induction of 331 
lipogenesis by fructose. Indeed, we observed a significantly higher expression and activation of 332 
SREBP1c in liver of FRT versus GLC mice, as confirmed by the resulting higher expression of 333 
ACC and by the greater hepatic TG accumulation. On the other hand, SREBP2 is equally 334 
hyperactivated in FRT and GLC mice, leading thus to similar expression of HMGR and thereby to 335 
similar level of cholesterol in liver. Although SCAP is the common activating protein of both 336 
SREBP1c and SREBP2, the existence of unidentified regulatory factors, such as nutritional status or 337 
food composition, that determine the fate of the SREBP/SCAP complex by distinguishing between 338 
SREBP-1c and SREBP-2 processing, has been supposed (17,37).   339 
Insulin is a well-known inducer of SREBP1c activity and hyperinsulinemia may contribute in 340 
hyperactivation of lipogenic pathway (7,8). However, in our experimental model FRT and GLC 341 
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mice, even showing altered glucose homeostasis, didn’t reach a condition of hyperisulinemia 342 
adequate to induce the de novo lipogenesis.  343 
We then hypothesized a possible interference of CML on SCAP/SREBP system. Indeed, a direct 344 
correlation between AGEs serum level and triglyceride level was found in children and adolescent 345 
with Type I diabetes  (13). Besides, the generation of CML has been observed  during high fat/high 346 
sugar diets (20,36) and  this has been attributed to lipid peroxidation processes (12). A relationship 347 
between intracellular lipid accumulation and increase in CML levels has also been recently 348 
demonstrated in an in vitro model of steatosis (12). Moreover, CML accumulation in the liver of 349 
obese individuals has been involved in hepatosteatosis development (41). This is also supported by 350 
a study showing that administration of pyridoxamine, an inhibitor of CML formation, reduces 351 
plasma triglyceride and cholesterol on Zucker obese rats (2). 352 
Several studies have indicated that interaction of CML with RAGE causes oxidative stress and 353 
activation of NFkB via multiple intracellular signal pathways (5,16). Our results demonstrated that 354 
both FRT- and GLC-chronic exposure increased hepatic RAGE expression, and consequently 355 
activates NFkB and inflammatory/fibrogenic signaling, at the same level. Therefore, the CML 356 
involvement in the higher lipogenesis occurring in FRT mice is not mediated by RAGE binding. 357 
A recent in vitro study in cultured mesangial cells highlights a direct causal role for CML in 358 
SREBPs activation by interfering with SCAP and thus driving SREBPs factors to elude its negative 359 
feedback control (52). The glycosylation of SCAP by Golgi enzymes plays an important role in the 360 
cycling of SCAP between the ER and the Golgi (31,51). In physiological conditions, high 361 
intracellular concentrations of cholesterol prevent transport of the SCAP-SREBP complex from the 362 
ER to the Golgi and downregulate SREBPs activation avoiding intracellular cholesterol and lipids 363 
overloading (10). CML administration in mesangial cells disrupted the SCAP-mediated feedback 364 
regulation of SREBPs, increasing SCAP gene transcription and protein stability, thereby enhancing 365 
the cycling of SCAP between the ER and the Golgi and prolonging SREBPs activation (52). 366 
Consistently, our immunofluorescence analysis suggested an interaction between CML and SCAP 367 
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which were extensively colocalized in the perinuclear zone of the hepatocytes in FRT mice. The 368 
result of coimmunoprecipitation technique further reinforced our hypothesis of a cross-link between 369 
CML and SCAP, indicating for the first time that a specific interference of CML in SCAP/SREBP 370 
system occurs also in vivo and, most notably, could be induced by FRT drinking. However, further 371 
experiments with specific CML inhibitors are needed for a conclusive demonstration of the causal 372 
role of fructose-derived AGEs in the activation of this specific signaling pathway. Recently, uric 373 
acid that generates from fructose metabolism has been suggested as a further mechanism 374 
contributing at least in part to the lipogenic effect of fructose feeding (23,24). Uric acid has been 375 
shown to induce mitochondrial oxidative stress and accumulation of citrate being the substrate for 376 
the de novo lipogenesis (23). It is known that oxidative stress is an important element in the 377 
glycoxidation process that leads to AGEs accumulation (15) and in some cases a direct positive 378 
correlation between uric acid and pentosidine levels has been reported (14,34).  379 
In summary, the present results improve our knowledge on fatty liver development and show an 380 
association between high levels of fructose-derived AGEs and activation of de novo lipogenesis, 381 
thus suggesting more caution in the even wider employment of fructose as added sweetener in foods 382 
and beverages. 383 
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Figure captions 545 
Fig. 1. FRT and GLC drinking affect glycaemic control and liver lipid accumulation. (A) Oral 546 
glucose tolerance test performed on 6 hrs fasting mice after 30 weeks of water, FRT or GLC 547 
drinking. (B) TG and cholesterol content in mice liver. (C-E) Representative 20x magnification 548 
photomicrographs of oil red staining on liver sections from CTRL (C), FRT (D), and GLC (E) mice. 549 
(F) Pathological grading in liver sections from CTRL, FRT and GLC mice according to the NAFLD 550 
activity score system by Kleiner et al. (21). Data are means ± S.D. of 8-10 mice per group. *P<0.05, 551 
**P<0.01 vs CTRL;  †P<0.05 vs FRT. 552 
 553 
Fig. 2. Expression analysis on SCAP/SREBP pathway. Western blotting analysis for SCAP (A), 554 
nuclear active SREBP1c (C) and SREBP2 (D), cytosolic inactive SREBP1c (F) and SREBP2 (G). 555 
(B,E,H) Histograms report densitometric analysis of 6-8 mice per group. *P<0.05, **P<0.01, 556 
***P<0.005 vs CTRL;  †P<0.05 vs FRT. 557 
 558 
Fig. 3. Expression analysis on markers of synthesis, -oxidation and secretion of hepatic 559 
lipids. Western blotting analysis for ACC (A), HMGR (C), ApoB100 (E) and CPT1-L (G). 560 
(B,D,F,H) Histograms report densitometric analysis of 6-8 mice per group. **P<0.01, ***P<0.005 561 
vs CTRL;  †P<0.05 vs FRT. 562 
 563 
Fig. 4. Expression analysis on RAGE/NFkB pathway. Representative western blotting analysis 564 
on total liver extracts for RAGE(A), on nuclear and cytosolic liver extracts showing NFkB 565 
activation (C), on total liver extracts for ICAM-1 and CTGF (E). (B,D,F) Histograms report 566 
densitometric analysis of 6-8 mice per group. *P<0.05, **P<0.01 vs CTRL. 567 
 568 
Fig. 5. Liver localization of SREBP1c, SCAP, CML, and MGO. Representative 40x/100x 569 
magnification photomicrographs of immunofluorescence analysis for SREBP1c (A,B), SCAP 570 
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(D,E), CML (G,I) and MGO (J,K) on 4m cryostatic liver sections. To assess aspecific staining, 571 
negative controls were prepared incubating sections only with secondary antibodies (anti-rabbit: 572 
C,F; anti-mouse: I,L).  573 
 574 
Fig. 6. CML interaction with SCAP. (A-F) Representative photomicrographs of double 575 
immunofluorescence for SCAP/CML. SCAP (A,D) was revealed by red fluorescence and CML 576 
(B,E) was revealed by green fluorescence. Colocalization is shown in merged images (C,E). (G) 577 
Immunoprecipitation studies on liver extracts. SCAP has been immunoprecipitated (IP) and 578 
membranes were incubated (IB) with anti-CML or anti-SCAP antibodies. (H) Histogram represent 579 
CML to SCAP band density ratio obtained by densitometric analysis of immunoprecipitation 580 
studies performed on 5-6 mice per group. Data are means ± S.D. Statistical significance: *P<0.05 581 
vs CTRL; †P<0.05 vs FRT.  582 
 583 
 584 
 585 
 586 
 587 
 588 
 589 
 590 
 591 
 592 
 593 
 594 
 595 
 596 
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Table 1. General parameters of mice after 30 weeks drinking water, FRT or GLC. Data are 597 
means ± S.D. of 8-10 mice per group. *P<0.05, **P<0.01, ***P<0.005 vs CTRL; †††P<0.005 vs 598 
FRT. 599 
 600 
 601 
 602 
 603 
 604 
 605 
 606 
 607 
 608 
 609 
 610 
 611 
 612 
 613 
 614 
 CTRL FRT GLC 
Drink intake             
(ml/die) 
3.7 ± 0.4 6.5 ± 0.5
***
 11.4 ± 3.8
***†††
 
Food intake             
(g/die) 
3.8 ± 0.9 2.6 ± 0.6
*
 2.0 ± 0.9
**
 
Caloric intake  
(Kcal/die) 
11.1 ± 2.8 11.3 ± 1.8 12.4 ± 2.1 
Body weight 
increase (g) 
12.4 ± 2.0 16.3 ± 2.5
***
 16.2 ± 2.4
***
 
Fasting glycemia 
(mmol/l) 
4.7 ± 1.0 7.2 ± 1.5
**
 7.1 ± 0.9
***
 
Insulinemia                  
(g/l) 
1.27 ± 0.07 2.13 ± 1.02 1.68 ± 1.03 
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Table 2. Plasma lipid profile of  mice after 30 weeks of water, FRT or GLC drinking. Data are 615 
means ± S.D. of 8-10 mice per group. *P<0.05, **P<0.01, ***P<0.005 vs CTRL; ††P<0.01 vs 616 
FRT. 617 
 618 
 619 
 620 
 621 
 622 
 623 
 624 
 625 
 626 
 627 
 628 
 629 
 630 
 631 
 632 
 633 
 CTRL FRT GLC 
TG 
(mmol/l) 
1.12 ± 0.18 1.60 ± 0.28
**
 1.34 ± 0.33 
Cholesterol   
(mmol/l) 
2.26 ± 0.20 3.10 ± 0.36
***
 2.68 ± 0.63 
HDL 
(mmol/l) 
1.46 ± 0.23 1.31 ± 0.24 1.23 ± 0.12
*
 
LDL 
(mmol/l) 
0.80 ± 0.17 1.44 ± 0.44
**
 0.95 ± 0.31 
NEFA               
(mg/dl) 
12.76 ± 1.58 9.75 ± 2.08
**
 15.29 ± 3.36
*††
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Table 3. Advanced glycated end-products evaluated by LC-MS in liver homogenates. Data are 634 
means ± S.D. of 8-10 mice per group. *P<0.05, **P<0.01, ***P<0.005 vs CTRL; †P<0.05, 635 
††P<0.01, †††P<0.005 vs FRT. 636 
 637 
 638 
 639 
 640 
 641 
 642 
 643 
 644 
 645 
 646 
 647 
 648 
 649 
 650 
 651 
 CTRL FRT GLC 
Pentosidine     
(pg/mg prot) 
n.d. 7.02 ± 3.98
*
 8.69 ± 0.92
***
 
GLAP               
(ng/mg prot) 
n.d. 0.36 ± 0.09
*
 2.20 ± 0.86
*†
 
GOLD             
(ng/mg prot) 
n.d. 148.1 ± 53.7
**
 98.5 ± 30.0
**
 
MOLD            
(ng/mg prot) 
n.d. 0.37 ± 0.24
*
 1.08 ± 0.11
***††
 
CML 
(ng/mg prot) 
0.57 ± 0.09 1.34 ± 0.14
***
 0.76 ± 0.03
*†††
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